Lipid nanocarriers: Potential for pulmonary delivery

International Conference and Exhibition on Lung Disorders & Therapeutics

July 13-15, 2015 Baltimore, Maryland, USA

Varsha B Pokharkar

Posters-Accepted Abstracts: J Pulm Respir Med

Abstract :

Lipid nanoparticles are extensively explored colloidal systems as a potential vehicle for site specific delivery of drugs to different organs or systems such as lung, brain, skin and lymphatic etc. Lipid nanoparticles such as solid lipid nanoparticles, nanostructured lipid carriers, liposomes etc. can help in improving efficacy while lowering toxicities of actives. Cellular uptake of drugs can also be enhanced by using lipid nanocarriers. Pulmonary route of delivery is an alternative non-invasive approach for both local and systemic delivery of therapeutic agents. Formulation of drug into inhalable form with sufficient stability and aerodynamic properties are the key challenges associated with the development of pulmonary drug delivery system. In course of our last few years endeavor to deliver drug loaded lipid nanocarriers for the treatment of local lung disorders, we have come up with efficient systems such as proliposomal dry powder for inhalation and nanostructured lipid carrier dry powder for inhalation. We have explored different approaches for the development of the lipid nanocarrierâ??s inhalation system. In one approach, we have developed proliposomes using single step spray drying method and in other we employed lyophilization technique for the successful development of powders for inhalation with desirable aerodynamic properties. Our studies demonstrate encapsulation of drugs such as rifapentine, montelukast, rosuvastatin etc. in lipid nanocarriers modifies the physicochemical as well as in-vivo pharmacokinetic properties. Pulmokinetic parameters such as Cmax, Tmax, AUC0- 24, KE, MRT and t1/2 were improved as compared to pure drug. An interesting finding was increased IC50 value of the encapsulated drug, thus reduced in-vitro cytotoxicity in pulmonary cells as compared to the conventional system. Our focus is on application of Quality by Design (QbD) principles for the development of inhalation delivery systems so as to comply with the current regulatory demand. Thus, our group is the first to report the successful application of QbD principles with design of experiment for the efficient development of proliposomal system for inhalation. The talk will highlight the findings of our research.